文献速递白血病

儿童急性髓系白血病治疗的成就与挑战:1987至2012年AML-BFM试验回顾性分析

Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.
PubMed 文献 · Leukemia · 2018-02-22

该研究回顾性分析1987至2012年入组基于人群的AML-BFM试验的1940例18岁以下儿童急性髓系白血病患者,发现5年总生存概率从49±3%(1987-1992)升至76±4%(2010-2012;p<0.0001),而无事件生存概率仅从41±3%升至50±2%(1993-1998;p=0.02)后保持稳定;无应答和复发率未变,早期死亡减少,无应答或复发后总生存概率及HSCT后总生存概率改善。

要点

  • 5年总生存概率从49±3%(1987-1992)升至76±4%(2010-2012;p<0.0001)。
  • 无事件生存概率仅从41±3%升至50±2%(1993-1998;p=0.02)后保持稳定。
  • 早期死亡从8.1%降至2.2%(p=0.001),无应答和复发后生存及HSCT后生存改善。

核心结论

  • 挽救治疗疗效主要贡献了儿童AML结局的改善,分析提示有必要将无法通过常规化疗治愈的患者更好地分配至早期「类挽救」治疗。

研究设计与样本

  • 回顾性分析1987至2012年入组基于人群的AML-BFM试验的1940例18岁以下儿童AML患者。

主要发现

  • 5年总生存概率从49±3%(1987-1992)升至76±4%(2010-2012;p<0.0001)。
  • 无事件生存概率仅从41±3%(1987-1992)升至50±2%(1993-1998;p=0.02),此后保持稳定。
  • 无应答率(p=0.08)和复发率(p=0.17)保持不变。
  • 早期死亡从8.1%降至2.2%(p=0.001)。
  • 无应答后5年总生存概率从13±5%(1987-1992)升至43±7%(2005-2010;p<0.0001),复发后从19±4%升至45±4%(p<0.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Overall survival (OS) of pediatric patients with acute myeloid leukemia (AML) increased in recent decades. However, it remained unknown whether advances in first-line treatment, supportive care, or second-line therapy mainly contributed to this improvement. Here, we retrospectively analyzed outcome and clinical data of 1940 pediatric AML patients (younger than 18 years of age), enrolled in the population-based AML-BFM trials between 1987 and 2012. While 5-year probability of OS (pOS) increased from 49 ± 3% (1987-1992) to 76 ± 4% (2010-2012; p < 0.0001), probability of event-free survival only improved from 41 ± 3% (1987-1992) to 50 ± 2% (1993-1998; p = 0.02) after introduction of high-dose cytarabine/mitoxantrone, but remained stable since then. Non-response and relapse rates stayed constant despite intensified first-line therapy (p = 0.08 and p = 0.17). Reduced fatal bleedings and leukostasis translated into fewer early deaths (8.1%vs. 2.2%; p = 0.001). Strikingly, pOS after non-response (13 ± 5% (1987-1992) vs. 43 ± 7% (2005-2010); p < 0.0001) or relapse (19 ± 4% vs. 45 ± 4%; p < 0.0001) improved. After 1999, more relapsed or refractory patients underwent hematopoietic stem cell transplantation (HSCT) with increased pOS after HSCT (29 ± 5% (1993-1998) vs. 50 ± 4% (2005-2010); p < 0.0001). Since efficacy of salvage therapy mainly contributed to better outcome in pediatric AML, our analysis indicates that a better allocation of patients, who cannot be cured with conventional chemotherapy, to an early "salvage-like" therapy is necessary.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Rasche M, Zimmermann M, Borschel L, et al. Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia. 2018. PMID: 29550834. doi:10.1038/s41375-018-0071-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。